Myriad Genetics: Gary A. King has joined Myriad Genetics (Salt Lake City) in the newly created position of executive vice president of international operations. He will oversee all aspects of Myriad's expansion into international markets, including operations, sales and marketing, regulatory approval, and pricing and reimbursement. King previously served as CEO of AverDx and before that was vice president of international operations at Biosite. [July 2010]

Ingen Biosciences: Karine Mignon-Godefroy, Ph.D., has been named director of research and development at Ingen Biosciences (Chilly-Mazarin, France), which develops and markets in vitro diagnostic kits for clinical use. Mignon-Godefroy joins Ingen from the blood virus division of Bio-Rad, where she was director of international projects. [July 2010]

Alverix: Richard C. Tarbox, III has been named CEO of Alverix (San Jose, Calif.), a developer of next-generation instrument and connectivity platforms for point-of-care testing. Tarbox was previously vice president of strategy management at Cardinal Health. [June 2010]

Siemens Healthcare : John Glaser, Ph.D. has been appointed CEO of the Health Services business unit of Siemens Healthcare (Malvern, Pa.). Glaser has served as vice president and chief information officer of Partners HealthCare since 1995 and recently acted as advisor to the Office of the National Coordinator and the Department of Health and Human Services on the HITECH portions of the federal government's stimulus bill. He will begin in his new role at Siemens on August 16, 2010.

AACC : Gary Myers, Ph.D.. has joined the staff of the American Association for Clinical Chemistry (AACC; Washington, D.C.) as vice president of programs and policy. Prior to joining AACC, Myers served as chief of the clinical chemistry branch at the Centers for Disease Control and Prevention in Atlanta. [June 2010]

The Blackstone Group : Arthur J. Higgins has joined Blackstone Healthcare Partners, the dedicated healthcare group of The Blackstone Group (New York). Higgins was previously chairman of the board of management of Bayer HealthCare. [June 2010]

Clarient : Surgical pathologist Neal S. Goldstein, M.D., has been named director of surgical pathology at Clarient (Aliso Viejo, Calif.), where he will report directly to chief medical officer Kenneth J. Bloom, M.D. Goldstein was most recently laboratory director at Advanced Diagnostics Laboratory and also spent the past year as a consulting pathologist for Clarient. From 2001 to 2008, he served as director of the molecular pathology laboratory at William Beaumont Hospital. [June 2010]

Biologics Consulting Group: Craig A. Halverson has been appointed as a senior consultant with Biologics Consulting Group (Alexandria, Va.), a regulatory affairs consulting firm. He was previously vice president of regulatory affairs and quality assurance at SciClone Pharmaceuticals. [June 2010]

CIGNA: Bertram L. Scott has been named as president of U.S. commercial operations at global health services company CIGNA (Bloomfield, Conn.). In the newly created position, Scott will have executive leadership responsibility for the company’s U.S. products, marketing, and national accounts. Scott most recently served as executive vice president and chief institutional development and sales officer of TIAA-CREF. [June 2010]

National Cancer Institute: President Barack Obama has selected Harold E. Varmus, M.D., to serve as the fourteenth director of the National Cancer Institute. He will replace John E. Niederhuber, M.D., who was appointed in 2006 by President George W. Bush. Varmus, a Nobel Prize laureate and former head of the National Institutes of Health, most recently served as president and chief executive officer of the Memorial Sloan-Kettering Cancer Center. [May 2010]

Immucor: Ralph A. Eatz will retire from his position as senior vice president and chief scientific officer and as a director of Immucor (Norcross, Ga.), effective May 30, 2010. Eatz joined Immucor as senior vice president of operations in 1982.

FSMB : Freda McKissic Bush, M.D., has assumed the position of chair of the Federation of State Medical Boards’ (FSMB) Board of Directors. The former president of the Mississippi State Board of Medical Examiners and a longtime leader in women’s health issues, Bush will lead the FSMB during 2010-2011. A national not-for-profit organization based in Dallas, the FSMB works to promte excellence in medical practice, licensure, and regulation. [May 2010]

FSMB: Michael P. Dugan, has been appointed chief information officer of the Federation of State Medical Boards (FSMB; Dallas). He will assist the senior management team with strategic planning, focusing on the development of FSMB’s position in the health care information technology arena. Dugan, who has spent the last four years as director of information technology planning at Parkland Health and Hospital System in Dallas, assumes his new position on June 7, 2010.

Aetna: Aetna ( Hartford, Conn.) has named Jeff D. Emerson head of its health care management ( HCM) organization. He is responsible for patient care support and management, promoting quality, and improving access to care for Aetna members. Emerson previously served as president of the NorthEnd Group, a privately held consulting company specializing in health care services and information technology. [April 2010]

Genetic Alliance: Ann Waldo, J.D., has been appointed senior counsel of Genetic Alliance ( Washington, DC). She is the nonprofit advocacy's organization's first in-house counsel. Waldo is also a partner in the law firm of Oldaker, Belair, & Wittie, LLP, providing counsel and advocacy on privacy and information management, with special focus on HIPAA and consumer protection health privacy. She previously served as chief privacy officer at Lenovo and Roche. [April 2010]

Roche NimbleGen: Frank Pitzer, Ph.D., has been appointed CEO of microarray maker Roche NimbleGen ( Madison, Wis.). He was previously head of divisional quality and regulatory affairs at Roche Diagnostics and was an active member of the diagnostics executive committee. [March 2010]

Affymetrix: Timothy Barabe has been named executive vice president and chief financial officer at microarray maker Affymetrix (Santa Clara, Calif.). He will replace John Batty. Barabe most recently served as senior vice president and chief financial officer at Human Genome Sciences. [March 2010]

CMS: The Centers for Medicare & Medicaid Services (CMS) has appointed Anthony Rodgers deputy administrator for strategic planning. He comes to CMS from Health Management Associates, where he served as principal consultant on health information technology, health system strategic planning, and health plan and system operations. Rodgers was previously the director of the state of Arizona Medicaid/State Children's Health Insurance programs. [March 2010

Pacific Biosciences: Susan Barnes has been appointed chief financial officer of Pacific Biosciences (Menlo Park, Calif.), a venture-backed molecular diagnostics company that is focused on integrating DNA sequencing into routine medical care. She was previously senior vice president of finance and chief financial officer of Intuitive Surgical. [March 2010]

Agilent Technologies: Robert Schueren has been appointed vice president and general manager of the genomics division at Agilent Technologies (Santa Clara, Calif.). He will be responsible for all of Agilent's genomics operations, including microarrays, QPCR, and life science reagents. Most recently, Schueren was global head of companion diagnostics, clinical biomarkers, and sample operations at Genentech/Roche. [February 2010]

Geisinger Health System: Victor G. Vogel, M.D., has been named director of cancer services at Geisinger Health System (Danville, Pa.). He will begin his new duties on May 3, 2010. Vogel currently serves as national vice president for research at the American Cancer Society

Clinical Laboratory Management Association: Mary Beth Hepp has been appointed CEO of the Clinical Laboratory Management Association (CLMA), which recently relocated from Wayne, Pa. to Chicago. Hepp previously served as executive director for the Society for Gastroenterology Nurses and Associates and also worked for the American Red Cross in a number of capacities. [February 2010]

FDA: Jeffrey E. Shuren, M.D., J.D., has been appointed director of the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA). He has served as acting director of CDRH since the August 2009 departure of Daniel Schultz, M.D. Since joining the FDA in 1998, Shuren has held policy and planning positions including acting deputy commissioner for policy, planning, and budget; associate commissioner for policy and planning; and medical officer in the Office of Policy. [January 2010]

RBC Capital Markets: Bill Bonello has joined the Minneapolis office of RBC Capital Markets, the corporate and investment banking arm of Royal Bank of Canada, where he has been appointed managing director and senior research analyst for healthcare. Bonello was previously senior vice president of investor relations at LabCorp. [January 2010]

AACC: Catherine Hammett-Stabler, Ph.D., has assumed the presidency of the American Association for Clinical Chemistry (AACC; Washington, D.C.). She is a professor in the Department of Pathology and Laboratory Medicine at the University of North Carolina and the director of the McLendon Clinical Laboratories Core Laboratory. Hammett-Stabler replaces AACC Past President Barbara M. Goldsmith, Ph.D., and come 2011, will be succeeded by President-Elect Ann M. Gronowski, Ph.D. [January 2010]


2009

Recombinant Data: Matvey B. Palchuk, M.D., M.S., has joined clinical data services company Recombinant Data Corp. (Newton, Mass.) as director of medical informatics. Palchuk, an instructor at Harvard Medical School, was previously an interlingua architect at Harvard's Center for Biomedical Informatics. He has also worked as a senior medical informatics specialist in the clinical informatics research and development group at the Partners HealthCare System. [December 2009]

ViraCor-IBT Laboratories (Kansas City, Missouri) has named Mark Roberts, Ph.D. as the company’s president and chief executive officer. Prior to joining ViraCor-IBT, Roberts served as general manager for Thermo Fisher Scientific’s Seradyn business unit. Roberts will replace the most recent company president, John Martin, who will assume the responsibilities of chief operating officer.

NeoGenomics: Jack G. Spitz has been appointed vice president of laboratory operations at NeoGenomics (Ft. Myers, Fla.). Spitz was previously senior executive director of operations for Dermpath Diagnostics, a division of Quest Diagnostics that was formerly part of Ameripath. Prior to joining Ameripath in 2006, Spitz served as director of operations for Genova Diagnostics. [December 2009]

On-Q-ity: Gary Palmer, M.D., JD, MPH, has been appointed chief medical officer of On-Q-ity (Waltham, Mass.), the cancer diagnostics company formed earlier this year via the merger of The DNA Repair Company and CELLective Diagnostics. On-Q-ity has raised $26 million in Series A funding. Palmer, a medical oncologist, was previously vice president of medical affairs at Genomic Health. [December 2009]

Affymetrix: Andrew J. Last, Ph.D., has been promoted to chief commercial officer of Affymetrix (Santa Clara, Calif.). His responsibilities will include sales, marketing, and service for the GeneChip maker, which transferred ownership of its CLIA-certified laboratory to Navigenics in March. Prior to joining Affymetrix, Last served on the leadership team of BD Biosciences Cell Analysis Unit, where he was vice president for global marketing and strategic planning and general manager of the San Diego-based Pharmingen business. [December 2009]

Health Discovery Corporation: Thomas Gallagher has been appointed executive vice president and managing director of global IP strategies at Health Discovery Corporation (Savannah, Ga.). He will be responsible for building new licensing and development relationships for the molecular diagnostics company. Gallagher spent 14 years on Wall Street as a securities and business transaction lawyer and was most recently a vice president at Goldman, Sachs & Co. [December 2009]

Insight Imaging: Clark Nielsen has been appointed senior vice president of sales for Insight Imaging (Lake Forest, Ill.), a provider of retail and wholesale diagnostic imaging services. He has 20 years of experience in sales roles at Philips Healthcare, where he most recently served as imaging systems region sales vice president. [November 2009]

Apposite Capital: Healthcare investment firm Apposite Capital (London) has appointed Eric Shiozaki, Ph.D., as an associate director. He will be based in San Francisco and will support Apposite’s primary and secondary investment activities in North America. Shiozaki was previously with Burrill & Company, a life sciences venture capital firm. Before that, he worked in technology transfer at the University of California, Los Angeles, where he managed a portfolio of healthcare technologies. [November 2009]

AACC:Ann M. Gronowski, Ph.D. has been elected president of the American Association for Clinical Chemistry (AACC; Washington, D.C.). She is an associate professor at Washington University School of Medicine in St. Louis in the departments of pathology and immunology, and obstetrics and gynecology as well as associate medical director of the clinical chemistry, serology and immunology laboratories at Barnes-Jewish Hospital. Gronowski will begin her term on January 1, 2010.

Pathology Inc.:Torrance, Calif.-based anatomic pathology and molecular diagnostic testing provider Pathology, Inc. has named Vicki DiFrancesco as CEO and Steve Pierce as CFO. DiFrancesco was most recently executive vice president of sales and marketing for Spectrum Laboratory Network, and Pierce was the former CFO of U.S. Pathology Labs, which was sold to LabCorp. The current Pathology Inc. CEO, Alfred Lui, M.D., will transition into the role of Chairman of the Board, as well as one of the company’s medical directors.

OraSure Technologies: Oral fluid diagnostics company OraSure Technologies (Bethlehem, Pa.) recently appointed Robert A. Gregg, Ph.D., to the position of vice president of regulatory affairs and quality assurance. Gregg was previously vice president of corporate regulatory affairs and quality systems at PerkinElmer and before that served as director of regulatory affairs at Roche Diagnostics. [October 2009]

The Carlyle Group: Gregory L. Summe has been appointed to the new position of vice chairman of global buyout at The Carlyle Group (Washington, D.C.). Summe, the former chairman and CEO of PerkinElmer, was most recently a senior adviser with Goldman Sachs Capital Partners. Summe led PerkinElmer from 1998 to 2009 and was previously with AlliedSignal, now Honeywell International. [October 2009]
Applied NeuroSolutions: Craig S. Taylor, Ph.D., has been appointed president and CEO of Applied NeuroSolutions (Vernon Hills, Ill.), a biotechnology company focused on developing diagnostics and therapeutics for Alzheimer's disease. He replaces Ellen R. Hoffing, who will remain chairman of the company's board of directors. Taylor was previously a partner at the private equity firm Adams Street Partners. He has also served in business development and research roles at G.D. Searle and Abbott Laboratories. [September 2009]

Vangent: Kerry Weems, former administrator of the Centers for Medicare and Medicaid Services, will join the IT contractor Vangent (Arlington, Va.) as senior vice president of health strategy. Weems ended his 28-year career in the federal government in January. His has held a number of senior positions in the Department of Health and Human Services, including deputy chief of staff, chief financial officer, and chief budget officer. [September 2009]

Quanterix: David Okrongly, Ph.D., has been named CEO of Quanterix (Cambridge, Mass.), which is developing a novel molecular diagnostic platform. He replaces interim CEO Nicholas Naclerio, Ph.D., who will continue in his position of chairman of the board. Okrongly comes to Quanterix from Siemens Healthcare Diagnostics Division, where he most recently served as senior vice president in charge of molecular diagnostics.

Roche Diagnostics: Roche (Basel, Switzerland) has appointed Daniel O’Day chief operating officer of its diagnostics division. He will replace Juergen Schwiezer, who will retire at the end of 2009. O’Day is currently president and CEO of Roche Molecular Diagnostics, a position he he has held since 2006. He previously served in various managerial, corporate planning, marketing, and sales roles with Roche Pharma. O'Day's new appointment will be effective January 1, 2010.

Quidel: Larry Mimms, Ph.D., has joined Quidel (San Diego, Calif.) as vice president of research and development. He has held a number of senior executive positions with Gen-Probe and most recently headed his own company, VDx, which focused on the development of a rapid diagnostic test for HIV. [August 2009]

Wake Forest University Baptist Medical Center: Thomas E. Sibert, M.D., has been named chief medical officer of Wake Forest University Baptist Medical Center (Winston-Salem,N.C.), a position created as part of a reorganization that the integrated health care system began two years ago. Sibert will oversee all quality and patient safety issues across inpatient and outpatient arenas. Sibert was previously associate vice chancellor, president of the Faculty Practice Group, and adjunct professor of psychiatry at the University of California, Los Angeles. [August 2009]

Response Biomedical: Livleen Kaler has been appointed chief financial officer and vice president of finance and administration at Response Biomedical (Vancouver), which develops, manufactures, and markets rapid diagnostic tests for use at the point of care. She has been with Response since 2006 and previously served as the director of finance at Infosat Communications, a subsidiary of Bell Canada. [August 2009]

U.S. Department of Health and Human Services: Todd Park, has been appointed chief technology officer for the U.S. Department of Health and Human Services (HHS). Reporting to Deputy Secretary of HHS William Corr, Park will be responsible for working with HHS leadership and agencies across the department on the innovative and creative use of information and technology to improve the health of Americans. Park is the co-founder of athenahealth, a provider of Internet-based business services for physician practices. [August 2009]

FDA: Michael R. Taylor, J.D., has been appointed senior advisor to the commissioner of the U.S. Food and Drug Administration (FDA). Taylor, an expert on food safety, is a research professor at George Washington University’s School of Public Health and Health Services. He is also a FDA veteran, having worked there as a litigating attorney and then as the FDA’s Deputy Commissioner for Policy (1991-1994), overseeing policy development and rulemaking. [July 2009

Imaging Dynamics Company: Swapan Kakumanu has been appointed executive vice president of Imaging Dynamics Company (IDC; Calgary, Alberta, Canada), a medical technology company focused on digital radiography. Kakumanu will take on new responsibilities for operational and geographic initiatives while remaining IDC's chief financial officer, a position he has held since 2006. [July 2009

ARUP Laboratories: Sherrie L. Perkins, MD, PhD, has been named chief medical officer ( CMO) and director of laboratories, effective July 1, 2009. Dr. Perkins will be taking over the responsibility from Edward R. Ashwood, MD, who will be transitioning into the role of president and chief executive officer. These transitions are coinciding with the retirement of the company’s founder and CEO, Carl R. Kjeldsberg, MD, on June 30, 2009. Dr. Perkins has been with ARUP Laboratories ( Salt Lake City, Utah) and the University of Utah for 19 years. During this time, she has served in numerous leadership roles including director of hematopathology, interim department chair, and, for the past three years, as a member of the ARUP Laboratories executive management team. She is a tenured professor at the University of Utah School of Medicine, is board certified in anatomic pathology and holds a special qualification in hematology. She received her PhD in biochemistry from the University of Miami, and earned her MD and completed her pathology residency at Washington University.

ARUP Laboratories: Edward R. Ashwood, M.D., director of laboratories and chief medical officer at ARUP Laboratories ( Salt Lake City, Utah), will assume the position of CEO on July 1, 2009. A 22-year veteran of ARUP, Ashwood is a tenured professor of pathology at the University of Utah School of Medicine and is board certified in clinical and chemical pathology. He replaces retiring CEO Carl R. Kjeldsberg, M.D., the ARUP co-founder who will continue to serve as chairman of the board.

Gen-Probe : Carl W. Hull has succeeded Henry L. Nordhoff as CEO of Gen-Probe ( San Diego, Calif.). Formerly Gen-Probe's president and chief operating officer, Hull also has joined the company's board of directors. Nordhoff, who had served as Gen-Probe's CEO since 1994, is now non-executive chairman following his re-election to the board at the company's annual meeting of stockholders. [June 2009]

Cowen Group: Jim Lilly has joined Cowen Group ( New York, N.Y.) as a managing director in the investment banking group and will lead the firm's health care services practice. Lilly was previously a managing director in Merrill Lynch's global health care group. Prior to joining Merrill in 2005, he was co-head of the health care group at Jefferies and began his health care career at Piper Jaffray. [June 2009]

Water Street Healthcare Partners : Robert B. Womsley has agreed to join Water Street Healthcare Partners (Chicago), a private equity firm focused exclusively on the health care industry. A senior partner with Citi Private Equity, Womsley will join Water Street Healthcare as a partner on July 1, 2009.

Pacific Biosciences : Eric Schadt , Ph.D., has been appointed chief scientific officer of Pacific Biosciences ( Menlo Park , Calif. ). He was previously executive scientific director of genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co. [May 2009]

CIGNA : Annmarie Hagan has been appointed executive vice president and chief financial officer of CIGNA Corporation ( Philadelphia , Penn. ). Since joining CIGNA in 1987, Hagan has held numerous leadership positions, including chief accounting officer and controller. Hagan succeeds departing CFO Michael W. Bell, who is resigning from CIGNA after 25 years with the company. [May 2009]

U.S. Food and Drug Administration: On May 18, the Senate confirmed President Barack Obama's nomination of Margaret Hamburg, M.D., to lead the U.S. Food and Drug Administration (FDA). Hamburg, who will be sworn in as the FDA's 21st commissioner, is a former New York City health commissioner and an expert in community health and bio-defense. During the Clinton administration, she served as secretary for policy and evaluation at the U.S. Department of Health and Human Services. Since 2001, she has been vice president for biological programs at the Nuclear Threat Initiative.

Centers for Disease Control and Prevention : President Barack Obama has selected Thomas Frieden, M.D., M.P.H., to head the Centers for Disease Control and Prevention (CDC). He is expected to take office in June. Frieden has served as Commissioner of the New York City Department of Health and Mental Hygiene since January 2002. A leading expert in tuberculosis control, Frieden previously spent five years in India assisting with national tuberculosis control efforts. Frieden began his career at the NYC Department of Health in 1990 as a CDC Epidemiologic Intelligence Service Officer working on a range of health issues. [May 2009]

Navigenics: Jonathan Lord, M.D., has been appointed president and CEO of consumer genomics company Navigenics (Foster City, Calif.). Lord, who most recently served as vice president and chief innovation officer at Humana, will assume his new roles on May 1. He replaces founding CEO Mari Baker, who departed in February to become CEO of PlayFirst, a video game company.

Signature Genomic Laboratories: Trilochan Sahoo, M.D. has joined Spokane, Washington-based Signature Genomics Laboratories as laboratory director. Prior to joining Signature, Sahoo spent six years as an assistant professor in the Department of Molecular and Human Genetics at Baylor College of Medicine in Houston, Texas. Sahoo received his M.D. in Clinical Microbiology from Christian Medical College and Hospital in Vellore, India, and completed his post-doctoral training at the Government of India Department of Biotechnology and the Duke University Medical Center Departments of Microbiology and Genetics ( Durham, North Carolina). He is certified by the American Board of Medical Genetics in Clinical Cytogenetics and completed his training under Signature President and CEO Lisa G. Shaffer, Ph.D. during her tenure at Baylor.

Centerview Partners: Merrill Lynch veterans Alan Hartman, Richard Girling, and Mark Robinson have agreed to join Centerview Partners ( New York, N.Y.), an investment banking advisory and private equity firm, to build the firm's healthcare practice. Hartman, formerly head of Americas mergers and acquisitions at Merrill Lynch, will be based in New York while Girling and Robinson, who previously served as global co-heads of Merrill's healthcare investment banking group, will be senior partners in Centerview's new London and San Francisco offices, respectively. [April 2009]

Quidel: Thomas Foley, Ph.D. will retire from his position as chief technology officer of Quidel ( San Diego, Calif.) effective May 31. Foley will continue as an employee through December 31 and will serve as a special advisor to the company in the interim. Foley’s career of more than 35 years includes leading the research and development divisions of several diagnostics and life sciences instrumentation companies. [April 2009]

Water Street Healthcare Partners: Hank Struik has joined the private equity firm Water Street Healthcare Partners ( Chicago, Ill.) as a senior executive advisor. He will focus on investment opportunities in the medical products sector, for which Water Street has committed up to $100 million in equity capital. Struik was previously a president of Cardinal Health, where he also held executive positions in sales, marketing, business development, and operations. [April 2009]

CMS: Jonathan Blum has been named as the Director, Center for Medicare Management. Jonathan joins CMS from Avalere Health, where he served as Vice President of Medicaid and Long-Term Care Practice. Jonathan will also serve as the Acting Director, Center for Drug and Health Plan Choice ( CPC). Abby Block, who has led CPC since 2005, will serve as Senior Advisor to the Administrator. Tim Hill, currently the Director, Office of Financial Management (OFM), will assume responsibility as the Acting Deputy Director, CPC. Deb Taylor, currently the Deputy Director of OFM, will serve as Acting Director of OFM, and Wes Perich will serve as the Acting Deputy Director, OFM. In the Office of Legislation, Amy Hall has been named Director and will develop the legislative agenda for the entire scope of CMS’s programs. Amy has more than 11 years of experience working for the U.S. House of Representatives in various capacities, most recently as an advisor to the Committee on Energy and Commerce (March 2009).

GE Healthcare: Pascale Witz has been appointed president and chief executive officer of GE Healthcare, Medical Diagnostics. In her most recent assignment, Witz led GE Healthcare’s Healthcare Systems interventional global business, which researches and develops innovative medical technologies to help physicians diagnose and treat disease earlier, faster, and more accurately. [March 2009]

U.S. Department of Health and Human Services: David Blumenthal, M.D. has been appointed national coordinator for health information technology. He replaces Robert Kolodner, M.D. Blumenthal most recently has been director of the Institute for Health Policy at the Massachusetts General Hospital/Partners HealthCare System and a professor at Harvard Medical School. [March 2009]

Critical Path Institute: Beatriz Rendon has joined the Critical Path Institute ( Tucson, Ariz.) as director of strategic alliances, a position in which she will develop partnerships and collaborations with other organizations, government, academia, philanthropic foundations, research institution, and corporations. She was formerly chief business officer at Tucson Unified School District. [March 2009]

Critical Path Institute: Steven Broadbent has joined the Critical Path Institute ( Tucson, Ariz.) as director of consortia operations, a position in which he will focus on helping the indepndent non-profit orgaization's several consortia execute their missions. He previously spent 26 years as an executive at IBM. [March 2009]

NeoGenomics: Cancer genetics testing provider NeoGenomics ( Ft. Myers, Fla.) has named Douglas M. VanOort executive chairman and interim chief executive officer (CEO) as part of a four-year contract. VanOort was the former executive vice president and chief financial officer of Corning Life Sciences, Inc. and then as senior vice president of operations at Quest Diagnostics. The testing company currently does not have a CEO, but its current board chairman and founder, Michael Dent, M.D. will step down, although he will remain on the board. As executive chairman, VanOort will spend approximately half of his working time on company affairs, as well as serving as interim CEO for the near future.

Quest Diagnostics: Jon R. Cohen, M.D. will join Quest Diagnostics ( Madison, N.J.) as senior vice president and chief medical officer on March 30, 2009. Cohen is the former chief policy advisor to New York Governor David Paterson and previously served as managing director of health industries services at PricewaterhouseCoopers. A 2006 candidate for lieutenant governor of New York, Cohen advised Senator John Kerry on healthcare policy during his presidential campaign in 2004.

Enzo Clinical Laboratories: Kevin Krenitsky, M.D. has been named president of New York City-based Enzo Clinical Labs, a subsidiary of Enzo Biochem. Krenitsky, who is replacing Shahram Rabbani, was most recently the CEO of Bioserve Biotechnologies Ltd, a global biotech company that validates, processes, and develops molecular diagnostics. Prior to Bioserve, he was Chief CEO of Parkway Clinical Laboratories ( Bensalem, Pa.), a clinical diagnostic lab providing comprehensive routine and esoteric testing, which was purchased by Rosetta Genomics ( Jersey City, New Jersey) in July 2008.

Mount Sinai Medical Center: Ira S. Nash, M.D. has been named senior vice president and chief medical officer of the Mount Sinai Medical Center ( New York, N.Y.). Since joining Mount Sinai in 1995, Nash has served as associate director of the Zena and Michael Wiener Cardiovascular Institute, chief of internal medicine at the affiliated James J. Peters Veterans Affairs Medical Center, and, most recently, interim chief medical officer. [March 2009]

Celerus Diagnostics: Jason Lusk has been appointed vice president of sales and marketing at Celerus Diagnostics ( Carpinteria, Calif.), maker of the Celerus Wave System for rapid immunohistochemistry in the anatomic pathology laboratory. Lusk was previously regional sales manager with Leica Microsystems, and his background includes positions in R&D, production, product development, and global product management. [March 2009]

White House Office for Health Reform: President Obama has named Nancy-Ann DeParle to be the director of the White Office for Health Reform. She will leave CCMP Capital, where she has been a manging director focusing on healthcare investments. Before joining CCMP, DeParle was administrator for what is now the Centers for Medicare and Medicaid Services during the Clinton administration. [March 2009]

Department of Health and Human Services: President Obama has officially nominated Kansas Governor Kathleen Sebelius as his secretary of health and human services. [March 2009]

LabCorp: Mark Elliott Brecher, M.D. has been appointed chief medical officer of LabCorp ( Burlington, N.C.). Brecher was previously vice chairman of the department of pathology and laboratory medicine at the McLendon Clinical Laboratories, University of North Carolina Hospitals. Myla Lai-Goldman, M.D., LabCorp's former chief scientific officer and medical director, left the company last December. [March 2009]

Xifin Inc.: Steve Zaniboni has been named chief financial officer of the San Diego-based Xifin Inc., a provider of revenue cycle management solutions for the lab industry. He was most recently chief financial officer of AviaraDX, which has been acquired by bioMerieux. In addition R. William (Bill) Taylor has been named vice president of marketing. Taylor comes to Xifin from Accelrys Inc., where he was vice president of marketing and corporate development.

Gen-Probe : Eric Lai has joined Gen-Probe ( San Diego , Calif. ) as senior vice president of research and development. He was previously vice president for pharmacogenetics experimental project coordination and analysis at GlaxoSmithKline. [Feb. 2009]

Artemis Health : Richard Rava has been appointed senior vice president of research and development at Artemis Health ( Menlo Park , Calif ), an early-stage company that develops prenatal diagnostic tests. Rava is the scientific co-founder of Affymetrix and was previously senior vice president of research and development there. [Feb. 2009]

Gen-Probe : Eric Tardif has joined Gen-Probe ( San Diego , Calif. ) as senior vice president, corporate strategy. Tardif was formerly a managing director in Morgan Stanley's healthcare investment banking group. [Jan. 2009]

Quidel : Douglas C. Bryant has been appointed president and CEO of Quidel ( San Diego , Calif. ). He will succeed retiring president and CEO Caren Mason on March 1. Bryant was previously executive vice president and COO of Luminex Corporation, where he managed its Bioscience Group, Luminex Molecular Diagnostics , manufacturing, R&D, technical operations, and commercial operations. [Jan. 2009]

3i : John Moore Jr. has joined the private equity firm 3i North America ( New York , N.Y. ) as a partner, with responsibility for the group’s healthcare strategy. Moore was formerly a managing director at Morgan Stanley and global head of healthcare investment banking there. [Jan. 2009]